Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 4103-4114

  Xiang, Dongxi ^a   Zheng, Yang ^b   Duan, Wei ^a   Li, Xiujing ^c   Yin, Jianjian ^c   Shigdar, Sarah ^a   O'Connor, Michael Liam ^a   Marappan, Manju ^a   Zhao, Xiaojuan ^d   Miao, Yingqiu ^c   Xiang, Bin ^c   Zheng, Conglong ^c  

^a DEAKIN UNIVERSITY   (Australia)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c DALIAN UNIVERSITY   (China)

^d Qingdao Central Hospital   (China)

Author keywords

Antiviral activity; H3N2; Influenza virus; Silver nanoparticles

Indexed keywords

OSELTAMIVIR; SILVER NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFECT; DRUG STABILITY; FEMALE; FLOW CYTOMETRY; HEMAGGLUTINATION; HISTOLOGY; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA A (H3N2); MDCK CELL; MOUSE; NONHUMAN; SURVIVAL; TRANSMISSION ELECTRON MICROSCOPY; VIRUS INHIBITION; VIRUS MORPHOLOGY;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MUS; ORTHOMYXOVIRIDAE; TACARIBE VIRUS;

ANTIVIRAL ACTIVITY; H3N2; INFLUENZA VIRUS; SILVER NANOPARTICLES;

ADMINISTRATION, INTRANASAL; ANALYSIS OF VARIANCE; ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; CELL SURVIVAL; DOGS; FEMALE; INFLUENZA A VIRUS, H3N2 SUBTYPE; LUNG; MADIN DARBY CANINE KIDNEY CELLS; METAL NANOPARTICLES; MICE; MICE, INBRED BALB C; SILVER;

EID: 84886864680     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/ijn.s53622     Document Type: Article

References (30)

1. Yoo DG, Kim MC, Park MK, et al. Protective effect of Korean red ginseng extract on the infections by H1N1 and H3N2 influenza viruses in mice. J Med Food. 2012;15(10):855-862.
2. Li W, Yang X, Jiang Y, et al. Inhibition of influenza A virus replication by RNA interference targeted against the PB1 subunit of the RNA polymerase gene. Arch Virol. 2011;156(11):1979-1987.
3. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009;459(7249): 931-939.
4. Lynch JP 3rd, Walsh EE. Influenza: evolving strategies in treatment and prevention. Semin Respir Crit Care Med. 2007;28(2):144-158.
5. Tharakaraman K, Raman R, Stebbins NW, Viswanathan K, Sasisekharan V, Sasisekharan R. Antigenically intact hemagglutinin in circulating avian and swine influenza viruses and potential for H3N2 pandemic. Sci Rep. 2013;3:1822.
6. Donnelly JJ, Friedman A, Martinez D, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med. 1995;1(6):583-587.
7. Webster RG, Laver WG, Air GM, Schild GC. Molecular mechanisms of variation in influenza viruses. Nature. 1982;296(5853): 115-121.
8. Peyre M, Fusheng G, Desvaux S, Roger F. Avian influenza vaccines: a practical review in relation to their application in the field with a focus on the Asian experience. Epidemiol Infect. 2009;137(1):1-21.
9. Poland GA, Jacobson RM, Ovsyannikova IG. Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis. 2009;48(9):1254-1256.
10. Haidari M, Zhang W, Ganjehei L, Ali M, Chen Z. Inhibition of MLC phosphorylation restricts replication of influenza virus - a mechanism of action for anti-influenza agents. PLoS One. 2011;6(6):e21444.
11. Mori Y, Ono T, Miyahira Y, Nguyen VQ, Matsui T, Ishihara M. Antiviral activity of silver nanoparticle/chitosan composites against H1N1 influenza A virus. Nanoscale Res Lett. 2013;8(1):93.
12. Tyler WJ, Petzold GC, Pal SK, Murthy VN. Experience-dependent modification of primary sensory synapses in the mammalian olfactory bulb. J Neurosci. 2007;27(35):9427-9438.
13. Baram-Pinto D, Shukla S, Perkas N, Gedanken A, Sarid R. Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethane sulfonate. Bioconjug Chem. 2009;20(8):1497-1502.
14. Elechiguerra JL, Burt JL, Morones JR, et al. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology. 2005;3:6.
15. Lu L, Sun RW-Y, Chen R, et al. Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther. 2008;13(2):253-262.
16. Rogers JV, Parkinson CV, Choi YW, Speshock JL, Hussain SM. A preliminary assessment of silver nanoparticle inhibition of Monkeypox virus plaque formation. Nanoscale Res Lett. 2008;3(4):129-133.
17. Speshock JL, Murdock RC, Braydich-Stolle LK, Schrand AM, Hussain SM. Interaction of silver nanoparticles with Tacaribe virus. J Nanobiotechnology. 2010;8:19.
18. Xiang DX, Chen Q, Pang L, Zheng CL. Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro. J Virol Methods. 2011;178(1-2):137-142.
19. Takizawa T, Matsukawa S, Higuchi Y, Nakamura S, Nakanishi Y, Fukuda R. Induction of programmed cell death (apoptosis) by influenza virus infection in tissue culture cells. J Gen Virol. 1993; 74 Pt 11:2347-2355.
20. Bradley DE. A study of the negative staining process. J Gen Microbiol. 1962;29:503-516.
21. Li HD, Zhang ZR, Zhang QX, Qin ZC, He DM, Chen JS. Treatment with exogenous hydrogen sulfide attenuates hyperoxia-induced acute lung injury in mice. Eur J Appl Physiol. 2013;113(6): 1555-1563.
22. Eckert EA. Influenza virus envelope protein: biological activity as a function of reassociation. Science. 1967;158(3800):527.
23. Wilson JC, von Itzstein M. Recent strategies in the search for new anti-influenza therapies. Curr Drug Targets. 2003;4(5):389-408.
24. Eckert EA. Envelope protein of influenza virus. I. Hemagglutinating activity of reassociated subunits. J Virol. 1967;1(5):920-927.
25. Trefry JC, Wooley DP. Silver nanoparticles inhibit vaccinia virus infection by preventing viral entry through a macropinocytosis-dependent mechanism. J Biomed Nanotechnol. 2013;9(9):1624-1635.
26. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature. 1994;371(6492): 37-43.
27. Radyukhin V, Fedorova N, Ksenofontov A, Serebryakova M, Baratova L. Cold co-extraction of hemagglutinin and matrix M1 protein from influenza virus A by a combination of non-ionic detergents allows for visualization of the raft-like nature of the virus envelope. Arch Virol. 2008;153(10):1977-1980.
28. Lara HH, Ayala-Nunez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology. 2010;8:1.
29. Boni MF, Gog JR, Andreasen V, Feldman MW. Epidemic dynamics and antigenic evolution in a single season of influenza A. Proc Biol Sci. 2006;273(1592):1307-1316.
30. Li Y, Leung P, Yao L, Song QW, Newton E. Antimicrobial effect of surgical masks coated with nanoparticles. J Hosp Infect. 2006;62(1): 58-63.